| pubmed-article:20118150 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20118150 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:20118150 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:20118150 | lifeskim:mentions | umls-concept:C0024501 | lld:lifeskim |
| pubmed-article:20118150 | lifeskim:mentions | umls-concept:C0027051 | lld:lifeskim |
| pubmed-article:20118150 | lifeskim:mentions | umls-concept:C0005821 | lld:lifeskim |
| pubmed-article:20118150 | lifeskim:mentions | umls-concept:C0155626 | lld:lifeskim |
| pubmed-article:20118150 | lifeskim:mentions | umls-concept:C0340293 | lld:lifeskim |
| pubmed-article:20118150 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:20118150 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:20118150 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:20118150 | lifeskim:mentions | umls-concept:C0070166 | lld:lifeskim |
| pubmed-article:20118150 | lifeskim:mentions | umls-concept:C0055729 | lld:lifeskim |
| pubmed-article:20118150 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:20118150 | lifeskim:mentions | umls-concept:C2825951 | lld:lifeskim |
| pubmed-article:20118150 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:20118150 | lifeskim:mentions | umls-concept:C1704243 | lld:lifeskim |
| pubmed-article:20118150 | lifeskim:mentions | umls-concept:C1554184 | lld:lifeskim |
| pubmed-article:20118150 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:20118150 | pubmed:dateCreated | 2010-2-17 | lld:pubmed |
| pubmed-article:20118150 | pubmed:abstractText | Optimal platelet inhibition is an important therapeutic adjunct in patients acute myocardial infarction (AMI) undergoing coronary stenting. Whether adjunctive cilostazol to dual antiplatelet therapy (triple antiplatelet therapy) can inhibit enhanced platelet reactivity in patients with AMI yet has not been determined. The aim of this study was to assess the degree of platelet inhibition by triple antiplatelet therapy in patients with AMI. | lld:pubmed |
| pubmed-article:20118150 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20118150 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20118150 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20118150 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20118150 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20118150 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20118150 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20118150 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20118150 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20118150 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20118150 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20118150 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20118150 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:20118150 | pubmed:issn | 1941-7632 | lld:pubmed |
| pubmed-article:20118150 | pubmed:author | pubmed-author:ParkSeong-Woo... | lld:pubmed |
| pubmed-article:20118150 | pubmed:author | pubmed-author:JeongYoung-Ho... | lld:pubmed |
| pubmed-article:20118150 | pubmed:author | pubmed-author:LeeSeung-Whan... | lld:pubmed |
| pubmed-article:20118150 | pubmed:author | pubmed-author:HwangJin-Yong... | lld:pubmed |
| pubmed-article:20118150 | pubmed:author | pubmed-author:KimIn-SukIS | lld:pubmed |
| pubmed-article:20118150 | pubmed:author | pubmed-author:ParkYongwhiY | lld:pubmed |
| pubmed-article:20118150 | pubmed:author | pubmed-author:KwakChoong... | lld:pubmed |
| pubmed-article:20118150 | pubmed:author | pubmed-author:HwangSeok-Jae... | lld:pubmed |
| pubmed-article:20118150 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20118150 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:20118150 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:20118150 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20118150 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20118150 | pubmed:pagination | 17-26 | lld:pubmed |
| pubmed-article:20118150 | pubmed:meshHeading | pubmed-meshheading:20118150... | lld:pubmed |
| pubmed-article:20118150 | pubmed:meshHeading | pubmed-meshheading:20118150... | lld:pubmed |
| pubmed-article:20118150 | pubmed:meshHeading | pubmed-meshheading:20118150... | lld:pubmed |
| pubmed-article:20118150 | pubmed:meshHeading | pubmed-meshheading:20118150... | lld:pubmed |
| pubmed-article:20118150 | pubmed:meshHeading | pubmed-meshheading:20118150... | lld:pubmed |
| pubmed-article:20118150 | pubmed:meshHeading | pubmed-meshheading:20118150... | lld:pubmed |
| pubmed-article:20118150 | pubmed:meshHeading | pubmed-meshheading:20118150... | lld:pubmed |
| pubmed-article:20118150 | pubmed:meshHeading | pubmed-meshheading:20118150... | lld:pubmed |
| pubmed-article:20118150 | pubmed:meshHeading | pubmed-meshheading:20118150... | lld:pubmed |
| pubmed-article:20118150 | pubmed:meshHeading | pubmed-meshheading:20118150... | lld:pubmed |
| pubmed-article:20118150 | pubmed:meshHeading | pubmed-meshheading:20118150... | lld:pubmed |
| pubmed-article:20118150 | pubmed:meshHeading | pubmed-meshheading:20118150... | lld:pubmed |
| pubmed-article:20118150 | pubmed:meshHeading | pubmed-meshheading:20118150... | lld:pubmed |
| pubmed-article:20118150 | pubmed:meshHeading | pubmed-meshheading:20118150... | lld:pubmed |
| pubmed-article:20118150 | pubmed:meshHeading | pubmed-meshheading:20118150... | lld:pubmed |
| pubmed-article:20118150 | pubmed:meshHeading | pubmed-meshheading:20118150... | lld:pubmed |
| pubmed-article:20118150 | pubmed:meshHeading | pubmed-meshheading:20118150... | lld:pubmed |
| pubmed-article:20118150 | pubmed:meshHeading | pubmed-meshheading:20118150... | lld:pubmed |
| pubmed-article:20118150 | pubmed:meshHeading | pubmed-meshheading:20118150... | lld:pubmed |
| pubmed-article:20118150 | pubmed:meshHeading | pubmed-meshheading:20118150... | lld:pubmed |
| pubmed-article:20118150 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20118150 | pubmed:articleTitle | Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. | lld:pubmed |
| pubmed-article:20118150 | pubmed:affiliation | Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea. | lld:pubmed |
| pubmed-article:20118150 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20118150 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:20118150 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20118150 | lld:pubmed |
